Stableford Capital II’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Stableford Capital II’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-6,639	Closed	-$282K	–	113
2017 Q3	$282K	Buy	6,639 +1,405	+27%	+$59.6K	0.2%	93
2017 Q2	$225K	Buy	+5,234	New	+$221K	0.18%	98

Other funds holding XPH

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

PVH

Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

HCIA

Hochman Cole Investment Advisors Deerfield, Illinois $255M AUM 23.27% 1-Year Est. Return

Stableford Capital II's XPH Position: Q4 2017 in Review

Stableford Capital II sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q4 2017, closing a stake of 6,639 shares — an estimated $282K sold.

Stableford Capital II first reported a position in XPH in Q2 2017 and held it in 2 quarters. The position peaked at $282K in Q3 2017. 85 funds tracked by Wall St. Rank hold XPH as of Q4 2017.

Stableford Capital II reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q4 2017 after selling out during the quarter.
Stableford Capital II sold 6,639 State Street SPDR S&P Pharmaceuticals ETF shares in Q4 2017, an estimated $282K.
Stableford Capital II first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q2 2017 and held it in 2 quarters.
Stableford Capital II's State Street SPDR S&P Pharmaceuticals ETF position peaked at $282K in Q3 2017.
85 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q4 2017.

Based on Stableford Capital II's 13F filing for Q4 2017, filed 10 Feb 2021.